<DOC>
	<DOCNO>NCT01938456</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability combination therapy trametinib docetaxel growth factor support Japanese subject Stage IV postoperative recurrence non-small cell lung cancer ( NSCLC ) . This study data use make decision Japanese development plan NSCLC . Six evaluable subject enrol dose level evaluate safety tolerability combination treatment . Dose-limiting toxicity assess first 21 day combination therapy .</brief_summary>
	<brief_title>Safety Tolerability Trametinib Combination With Docetaxel Japanese Subjects With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible enrolment study must meet following criterion : Provided sign write informed consent . 20 year old old ( time consent obtain ) . Histologically cytologically confirm NSCLC . Diagnosed Stage IV , postoperative recurrence . Tumor progression receive one prior platinumbased chemotherapy . Targeted therapy ( gefitinib , crizotinib , etc ) significant hematological toxicity count . Performance status score â‰¤1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . All prior treatmentrelated toxicity must CTCAE v4.0 &lt; =Grade 1 ( except alopecia ) time enrollment . Women childbearing potential must negative serum pregnancy test within 7 day first dose study treatment agree use effective contraception throughout treatment period , 4 month last dose study treatment . Men must agree use effective contraception throughout treatment period docetaxel . Adequate organ baseline function define Hematology : absolute neutrophil count &gt; =1.5 x 10^9/Liter ( L ) , hemoglobine &gt; =9 gramms/decilitre , platelet &gt; ==100 x 10^9/L , Prothrombine time/international normalize ratio activate partial thromboplastine time &lt; =1.5 x upper limit normal ( ULN ) Hepatic : albumin &gt; =2.5 grams/decilitre , total bilirubine &lt; =ULN , aspartate aminotransferase alanine aminotransferase &lt; =1.5 x ULN alkaline phosphatase &gt; =ULN &lt; =2.5 ULN alkaline phosphatase &lt; ULN . Renal : creatinine &lt; =1.5 x ULN calculate creatinine clearance &gt; =50 millilter ( mL ) /minute . Cardiac : leave ventricular ejector factor &gt; =lower limit normal echocardiogram . Negative Hepatitis B surface ( HBs ) antigen , Hepatitis virus B core ( HBc ) antibody , HBs antibody Hepatitis C Virus ( HCV ) antibody . If HBs antigen negative either HBc HBs antibody positive , Hepatitis B Virus ( HBV ) DNA measure . Exclusion Criteria Anticancer therapy ( include chemotherapy , radiation therapy , immunotherapy , biologic therapy , hormonal therapy , major surgery , tumor embolization investigational therapy ) within last three week , follow exception : six week prior nitrosourea mitomycin C two week anticancer therapy give continuously weekly basis limit potential delayed toxicity . Previously treat docetaxel Previously treat MEK inhibitor Current use prohibit medication Suspected currently clinically significant infectious disease . Hypersensitivity polysorbate 80 . Hypersensitivity filgrastim growth factor History current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) : History RVO CSR , predispose factor RVO CSR ( e.g. , uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) Visible retinal pathology assess ophthalmologic exam consider risk factor RVO CSR : Evidence new optic disc cupping , Evidence new visual field defect automate perimetry , Intraocular pressure &gt; 21 millimeter mercury ( mmHg ) measure tonography . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . Subjects require treatment condition exclude . History another malignancy . Exception : Subjects diseasefree 5 year , subject history completely resect nonmelanoma skin cancer situ carcinoma eligible . Any serious and/or unstable preexist medical ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure . History interstitial lung disease pneumonitis Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal , metabolic , cardiac disease ) . History evidence cardiovascular risk include follow : LVEF &lt; LLN A QT interval correct heart rate use Bazett 's formula &gt; =480 millisecond . History evidence current clinically significant uncontrolled arrhythmia . Exception : Subjects control atrial fibrillation &gt; 30 day prior study treatment eligible . Currently treat subject exclude . History acute coronary syndrome ( include myocardial infarction angina ) , coronary angioplasty , stenting within 6 month prior randomization . Subjects currently treat anticoagulant . History evidence current &gt; = Class II congestive heart failure define New York Heart Association . Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mmHg control antihypertensive therapy . Subjects intracardiac defibrillator permanent pacemaker . Known cardiac metastasis . Have know immediate delay hypersensitivity reaction idiosyncrasy dimethyl sulfoxide ( DMSO ) . Lactating female Known Human Immunodeficiency Virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>GSK1120212 ( trametinib )</keyword>
	<keyword>Japanese</keyword>
	<keyword>Phase Ib</keyword>
	<keyword>combination therapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>MEK inhibitor</keyword>
</DOC>